MedMira Inc. announced that its Board of Directors appointed Marvyn Robar and Colin MacGillivray as Directors to serve until the next annual shareholder meeting. Dr. Shou-Ching Tang retired from the Board of Directors after 12 years of service. These changes were effective May 2, 2014.

The Board elected Mr. Robar as the company's first non-executive Chairman. Hermes Chan, CEO of MedMira, who served as interim Chairman, will remain as the member of the Board. The appointment of Mr. Robar, supports the Board's commitment to the advancement of MedMira's corporate governance practices and policies and enables the implementation of industry best practices within the company.

Prior to his retirement from the Government of Nova Scotia 2013, Mr. Robar served as the Vice President, Investment, Department of Economic and Rural Development and Tourism, in charge of the $700 million economic development fund and as President of the Nova Scotia Strategic Opportunities Fund Inc. Dr. MacGillivray has over 20 years of experience including finance and operating experience in life sciences across multiple geographies with Elan Pharmaceuticals Inc., Lundbeck Inc. and Biolytical Laboratories, along with broader experience from a range of other industries.